Last reviewed: June 6, 2026
Last updated: June 6, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a GLP-1 receptor agonist originally developed for diabetes, has become widely used for weight management because it reduces appetite and increases feelings of fullness. Clinical research demonstrates that patients taking semaglutide lose significantly more weight than those on diet and exercise alone, though the exact amount varies based on genetics and individual response patterns.
Average Weight Loss Outcomes with Semaglutide Injection
The landmark STEP clinical trials showed that patients receiving semaglutide lost an average of 10-15% of their body weight over 68 weeks of treatment. In the STEP 1 trial specifically, participants lost approximately 15.3% of baseline weight, compared to 2.6% in the placebo group. These outcomes represent one of the most significant weight loss results achieved with a non-surgical medical intervention.
Real-world results from compounding pharmacies show similar patterns, though individual outcomes range from 5% to 20% body weight loss depending on starting weight, age, and adherence to the treatment protocol. A patient weighing 250 pounds might expect to lose 12-37 pounds over six months, though results accumulate gradually rather than dramatically. The weight loss trajectory typically shows faster initial loss in the first 12-16 weeks, followed by a more gradual decline as the body stabilizes at a new set point.
How Genetics Influence Your Semaglutide Weight Loss
Genetic variation in the GLP-1 receptor gene (GLP1R rs6923761) and the FTO gene (rs9939609) significantly affects how your body responds to semaglutide therapy. Some patients carry genetic variants that enhance receptor sensitivity, allowing them to achieve greater weight loss with standard doses. Others may require dose optimization or longer treatment periods to reach similar outcomes. PlexusDx's Precision Peptide Genetic Test maps these key pathways to predict your individual response likelihood before treatment begins.
The GIPR gene (rs1800437) and MC4R gene (rs17782313) variants also influence appetite regulation and energy expenditure, meaning patients with certain genetic profiles may experience faster appetite suppression and better weight loss consistency. Understanding your genetic predisposition helps PlexusDx providers personalize your starting dose and timeline expectations, transforming weight loss from guesswork into precision medicine. This genetic insight explains why some patients lose 25+ pounds in three months while others progress more gradually—both are normal responses shaped by biological differences.
Timeline: When You'll See Weight Loss Results
Most patients notice appetite reduction and modest weight loss within the first two to three weeks of starting compounded semaglutide injection, though this initial phase is often water weight and reduced food volume rather than fat loss. By weeks 4-8, measurable weight loss becomes consistent, averaging 1-2 pounds per week as your body adjusts to the medication's appetite-suppressing effects. Significant visible changes typically appear around the 8-12 week mark, when patients have lost 5-10% of baseline body weight.
The plateau phase usually occurs between weeks 16-24, when weight loss slows or temporarily stops as your metabolism adapts to the new calorie intake level. This is a normal physiological response and not a sign that treatment has stopped working. Continuing treatment through this phase, combined with consistent nutrition and movement habits, typically leads to renewed weight loss momentum in months 4-6. Your PlexusDx provider can adjust your dose strategy if needed to support continued progress.
Maximizing Weight Loss: Dose Optimization and Lifestyle Integration
Semaglutide's weight loss effectiveness depends partly on finding your optimal therapeutic dose—the point where appetite suppression is strong without causing excessive nausea or side effects. PlexusDx compounded semaglutide injection allows flexible dose titration starting as low as 0.25mg weekly, with increases every 4 weeks based on tolerance and response. Your dose may need to go up. Your price won't—PlexusDx maintains flat monthly pricing regardless of dose level, removing barriers to appropriate treatment escalation.
Weight loss outcomes also depend heavily on what you eat when appetite is suppressed. Patients who prioritize protein-rich foods, adequate hydration, and regular physical activity (even light walking) achieve more durable weight loss and better body composition preservation compared to those who simply eat less overall. Semaglutide works best as part of a comprehensive approach that includes mindful eating, movement, and stress management—not as a standalone solution that replaces behavioral change.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Will I lose weight on a lower dose of compounded semaglutide?
Yes, weight loss occurs at lower doses, though typically less dramatically than at higher therapeutic doses. Many patients experience appetite reduction and 5-8% weight loss at starting doses of 0.25-0.5mg weekly. PlexusDx providers often recommend gradual dose increases over 16-20 weeks to balance effectiveness with tolerability, allowing your body to adapt while optimizing results.
How does compounded semaglutide compare to the brand-name versions?
Compounded semaglutide from licensed 503A pharmacies contains the same active ingredient as brand-name versions and produces comparable weight loss outcomes when dosed appropriately. The key difference is accessibility and affordability—PlexusDx compounded semaglutide injection starts at $149/month with no insurance required, making treatment available to patients regardless of coverage status or prior authorization delays.
Can the Precision Peptide Genetic Test predict how much weight I'll lose?
The Precision Peptide Genetic Test identifies your genetic variants in GLP1R, GIPR, FTO, and MC4R pathways, which influence appetite regulation and metabolic response to semaglutide. While genetics don't determine exact weight loss amounts, they help predict whether you'll be a rapid responder, moderate responder, or slow responder—allowing PlexusDx providers to set realistic timelines and optimize your treatment strategy from the start. The test costs $99 after your first month of treatment.
What happens to weight loss if I stop taking semaglutide?
Weight typically begins to return within weeks of discontinuing semaglutide, as appetite regulation returns to pre-treatment patterns. Most patients regain 30-50% of lost weight within one year after stopping the medication. This doesn't mean treatment failed—it reflects the chronic nature of weight management. Many patients use semaglutide long-term or resume treatment periodically to maintain results, viewing it similarly to how hypertension or diabetes requires ongoing medication management.
Does PlexusDx offer semaglutide in oral form if injections aren't right for me?
Yes, PlexusDx offers Oral Semaglutide starting at $249/month for patients who prefer tablet formulations. Oral semaglutide typically produces slightly lower weight loss outcomes than the injection form (8-12% vs. 10-15%) due to absorption differences, but it remains highly effective for many patients. PlexusDx can help you choose the delivery method that best fits your lifestyle and clinical response.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
What is Tirzepatide Good For? Exploring Its Benefits and Uses
Is GLP-1 Bad for You? Understanding the Benefits and Risks of GLP-1 Drugs